Rigidified analog of MPPG (Cat. No. 0853); selective group II metabotropic glutamate receptor antagonist (IC50 = 30 μM) with no significant effect on group I and III mGlu receptors at concentrations up to 1 mM. Increases extracellular glutamate concentrations and possesses unusual inverse agonist-like action.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 100 mM in 1.1eq. NaOH|
Preparing Stock Solutions
The following data is based on the product molecular weight 257.18. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.89 mL||19.44 mL||38.88 mL|
|5 mM||0.78 mL||3.89 mL||7.78 mL|
|10 mM||0.39 mL||1.94 mL||3.89 mL|
|50 mM||0.08 mL||0.39 mL||0.78 mL|
References are publications that support the products' biological activity.
Krenz et al (2000) Group I, II and III mGluR compounds affect rhythm generation in the gastric circuit of the crustacean stomatogastric ganglion. J.Neurophysiol. 83 1188 PMID: 10712449
Xi et al (2002) Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens. J.Pharmacol.Exp.Ther. 300 162 PMID: 11752112
If you know of a relevant reference for (RS)-APICA, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: (RS)-APICA, supplier, Selective, group, II, antagonists, mGlur, Group, Receptors, mGlu2, mGlu3, mGluR2, mGluR3, Glutamate, Metabotropic, Glutamate, (Metabotropic), Group, II, Receptors, Glutamate, (Metabotropic), Group, II, Receptors, Tocris Bioscience
1 Citation for (RS)-APICA
Citations are publications that use Tocris products. Selected citations for (RS)-APICA include:
Scholler (2017) HTS-compatible FRET-based conformational sensors clarify membrane receptor activation. Nat Chem Biol 13 372 PMID: 28135236
Do you know of a great paper that uses (RS)-APICA from Tocris? If so please let us know.
Reviews for (RS)-APICA
There are currently no reviews for this product. Be the first to review (RS)-APICA and earn rewards!
Have you used (RS)-APICA?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.